Physician profile
Robert Rankin
NPI 1588639066
$1,394.35
in general payments reported to CMS, 2019-2025
19 companies · $141 in 2025
The $141 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $115 · 2021: $229 · 2022: $99.30 · 2023: $332 · 2024: $188 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $237.71 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $210.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $127.11 | 2023 | Farxiga |
| Organon LLC | $119.30 | 2021-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $96.76 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Pfizer INC. | $92.49 | 2019-2024 | |
| Therapeuticsmd, INC. | $89.29 | 2020-2021 | |
| Amgen INC. | $68.05 | 2019-2022 | |
| Virtus Pharmaceuticals LLC | $67.74 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $54.77 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $52.04 | 2019-2020 | |
| Millicent US INC | $35.35 | 2025 | Intrarosa, Femlyv |
| Mayne Pharma Commercial LLC | $31.27 | 2021-2022 | |
| Scynexis, INC. | $25.85 | 2021-2022 | |
| Evofem Biosciences, INC. | $22.12 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $18.64 | 2021 | |
| Duchesnay USA Incorporated | $16.02 | 2019 | |
| Lupin INC. | $14.92 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rankin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.